Can I Take Ashwagandha with Zepbound (Tirzepatide)?

Why This Question Comes Up

Zepbound (tirzepatide) entered the weight management market after FDA approval in November 2023 for adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related comorbidity [1]. Ashwagandha is one of the most popular adaptogenic supplements in the United States, with retail sales exceeding $198 million in 2023 according to the American Botanical Council [2]. Patients combining the two want to know if ashwagandha will blunt tirzepatide's weight loss, cause a dangerous interaction, or require any special monitoring.

No Indexed Drug-Drug Interaction Exists

The FDA prescribing information for Zepbound does not list ashwagandha or any botanical supplement as a contraindication or precaution [1]. The Natural Medicines Comprehensive Database, which catalogs over 100,000 supplement-drug interaction pairs, contains no monograph entry for a tirzepatide-ashwagandha interaction. PubMed returns zero results for the combined search terms "tirzepatide AND ashwagandha" or "tirzepatide AND Withania somnifera" as of May 2026.

Why the Absence of Data Is Not the Same as Safety

The lack of a cataloged interaction does not equal proof of safety. It means the combination has never been studied in a controlled trial. Both compounds influence overlapping metabolic axes (cortisol, thyroid, glucose), so pharmacodynamic effects could combine in ways that matter clinically. The sections below break down each overlap.

How Tirzepatide Works

Tirzepatide is a once-weekly injectable peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor [3]. This dual mechanism produces greater glycemic control and weight reduction than GLP-1-only agents. It slows gastric emptying, increases insulin secretion in a glucose-dependent manner, and reduces appetite through central hypothalamic signaling.

Weight Loss Efficacy in SURMOUNT-1

In the SURMOUNT-1 trial (N=2,539), participants receiving tirzepatide 15 mg lost a mean of 20.9% of body weight at 72 weeks compared to 3.1% with placebo [4]. That effect size sets a high bar. Any supplement a patient adds should, at minimum, not interfere with it.

Metabolism and Clearance

Tirzepatide is a peptide. It is degraded by proteolytic enzymes, not by cytochrome P450 (CYP) liver enzymes [3]. This distinction matters because most herb-drug interactions occur through CYP inhibition or induction. Ashwagandha's withanolides have shown mild CYP2D6 and CYP3A4 modulation in vitro [5], but because tirzepatide bypasses hepatic CYP metabolism entirely, those effects are irrelevant to this pairing.

How Ashwagandha Works

Ashwagandha (Withania somnifera) contains withanolides, a class of steroidal lactones, as its primary bioactive compounds. Traditional Ayurvedic use spans centuries, but modern clinical interest centers on three pharmacological effects: cortisol reduction, thyroid hormone modulation, and mild anxiolysis through GABAergic activity [6].

Cortisol-Lowering Effect

A double-blind RCT by Chandrasekhar et al. (N=64) found that 300 mg of ashwagandha root extract twice daily reduced serum cortisol by 30.5% over 60 days compared to placebo [7]. The Endocrine Society notes that sustained cortisol reduction can alter glucose metabolism, fat distribution, and appetite regulation [8]. For a patient on tirzepatide who already has suppressed appetite and shifting metabolic parameters, this additive cortisol effect warrants attention rather than alarm.

Thyroid Hormone Modulation

A 2018 RCT by Sharma et al. (N=50) in adults with subclinical hypothyroidism showed that ashwagandha 600 mg daily for 8 weeks significantly increased serum T4 (from 7.07 to 8.74 μg/dL, P<0.001) and normalized TSH levels relative to placebo [9]. The clinical implication: patients already on thyroid replacement therapy, or those whose thyroid function shifts during weight loss, could see unpredictable thyroid lab changes if they add ashwagandha. The American Thyroid Association recommends rechecking TSH 6 to 8 weeks after any change in a medication or supplement that could affect thyroid function [10].

Pharmacodynamic Overlap: Where the Real Concern Lives

Because tirzepatide is not metabolized by CYP enzymes, the interaction risk is not pharmacokinetic. It is pharmacodynamic, meaning the two substances could amplify each other's physiological effects without directly altering each other's blood levels.

Blood Glucose

Tirzepatide lowers fasting plasma glucose by 36 to 50 mg/dL in patients with type 2 diabetes, depending on dose [3]. Ashwagandha has demonstrated modest glucose-lowering effects in animal models and small human studies. A 30-day trial by Andallu and Radhika (N=12) reported a fasting blood glucose reduction comparable to an oral hypoglycemic agent [11]. The evidence is weak, but if a patient is already on tirzepatide and experiencing post-meal glucose dips, even a small additive effect from ashwagandha could push glucose into symptomatic hypoglycemia range (below 70 mg/dL).

Cortisol and Weight Regain Risk

Chronic cortisol elevation promotes visceral fat storage. Tirzepatide reduces body weight partly by lowering caloric intake and partly through improved insulin sensitivity. If ashwagandha genuinely lowers cortisol by 30% as the Chandrasekhar data suggest [7], the theoretical result would be complementary, not antagonistic. Lower cortisol should support fat loss, not impair it. The concern is not that ashwagandha will block tirzepatide's action. The concern is that abruptly stopping ashwagandha after months of use could allow cortisol rebound, potentially destabilizing the metabolic environment that tirzepatide has helped create.

Thyroid Function During Active Weight Loss

Weight loss itself alters thyroid hormone levels. A 2014 study in Obesity (N=191) found that a mean weight loss of 13.4 kg was associated with a significant decline in free T3 [12]. Tirzepatide's substantial weight reduction effect means patients may already be experiencing thyroid shifts. Adding ashwagandha, which raises T4 and lowers TSH, introduces a second variable into an already changing hormonal picture. This is manageable with monitoring but should not be ignored.

What Clinicians Recommend

Dr. Karl Nadolsky, an endocrinologist and obesity medicine specialist, has stated publicly: "I don't tell patients they can't take adaptogens, but I do insist on knowing about everything they're taking so I can interpret their labs correctly" [13]. That position reflects the consensus among obesity medicine physicians.

The American Association of Clinical Endocrinology (AACE) Guidance

The 2023 AACE Clinical Practice Guideline for obesity management recommends that clinicians "obtain a complete list of all medications, supplements, and herbal products at every visit" because supplements can confound lab interpretation and contribute to adverse effects that mimic drug side effects [14]. This guidance applies directly to the tirzepatide-ashwagandha combination.

Practical Monitoring Protocol

For patients who choose to take both, a reasonable approach includes the following steps. Check a baseline thyroid panel (TSH, free T4, free T3) and fasting glucose before starting ashwagandha. Recheck at 8 weeks, then every 3 to 6 months. If TSH drops below 0.4 mIU/L or free T4 rises above the reference range, discontinue ashwagandha and recheck in 6 weeks. Track any new symptoms of hypoglycemia (shakiness, sweating, lightheadedness) particularly in the first month.

Dose Separation and Timing

Tirzepatide is injected subcutaneously once weekly. It reaches peak plasma concentration in approximately 8 to 72 hours depending on the injection site [3]. Ashwagandha is taken orally, typically once or twice daily, with food.

No Required Timing Window

Because there is no pharmacokinetic interaction between the two, there is no evidence-based reason to separate doses by a specific number of hours. This differs from pairs like levothyroxine and calcium, where mineral binding in the gut creates a true absorption conflict. Tirzepatide bypasses the GI tract entirely via subcutaneous injection, and ashwagandha does not bind peptides in the bloodstream.

Gastric Emptying Consideration

One indirect interaction worth noting: tirzepatide delays gastric emptying [3]. This means any oral supplement taken alongside it may be absorbed more slowly. For ashwagandha, which has a broad therapeutic window and no narrow pharmacokinetic target, slower absorption is unlikely to matter clinically. Patients should take ashwagandha with food as usual, without adjusting timing around their weekly injection.

Who Should Avoid the Combination

Not every patient on Zepbound should add ashwagandha freely. Certain populations face higher risk from the pharmacodynamic overlap.

Patients with Thyroid Disease

Anyone with Graves' disease, Hashimoto's thyroiditis, or active thyroid nodules should avoid ashwagandha unless cleared by an endocrinologist. Ashwagandha's thyroid-stimulating effect, documented in the Sharma trial [9], could worsen hyperthyroidism or complicate dose adjustments of levothyroxine.

Patients on Insulin or Sulfonylureas Alongside Tirzepatide

If a patient is using tirzepatide for type 2 diabetes and is also on insulin or a sulfonylurea, adding ashwagandha introduces a third glucose-lowering variable. The FDA label for Zepbound already warns about hypoglycemia risk when combined with insulin secretagogues [1]. Ashwagandha would compound that risk.

Pregnant or Breastfeeding Patients

Ashwagandha is classified as "likely unsafe" during pregnancy by the Natural Medicines Comprehensive Database due to abortifacient properties observed in animal studies [6]. Tirzepatide is also not recommended during pregnancy. Patients who become pregnant should stop both.

If You Are Already Taking Both

Many patients discover this article after they have been taking ashwagandha and Zepbound together for weeks or months. That is not cause for panic. The absence of reported adverse events in the literature, combined with the lack of a pharmacokinetic interaction, suggests that short-term concurrent use at standard doses (300 to 600 mg daily of ashwagandha root extract) carries low absolute risk.

Steps to Take Now

Tell your prescribing clinician. Request a thyroid panel and fasting glucose at your next visit. Note any new symptoms you have experienced since starting the combination, particularly changes in heart rate, energy level, or blood sugar symptoms. If labs are normal and you feel well, the decision to continue is between you and your provider.

Bottom Line

Ashwagandha does not block or reduce tirzepatide's weight loss effect through any known mechanism. The two substances do not share metabolic pathways. The risk, such as it is, comes from overlapping pharmacodynamic effects on thyroid hormones, cortisol, and blood glucose. A thyroid panel at baseline and every 3 to 6 months, combined with open communication with your prescriber, is sufficient to use both safely at standard doses.